Advitech to transfer business operations to subsidiary Botaneco Speciality Ingredients

NewsGuard 100/100 Score

Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announces today its intention to close its office on boulevard Lebourgneuf in Quebec City. Advitech's business operations will be transferred to its subsidiary in Calgary, Botaneco Speciality Ingredients Inc. ("Botaneco"). Following the merger of Advitech and Botaneco in November 2009, this is a significant step towards integrating and optimizing operations of the combined entity.

"This move will help realize expected synergies between Advitech and Botaneco in consolidating our operations, aligning sales and marketing efforts and reducing costs to better serve our customers" noted Michael Stangel, President and Chief Executive Officer of Advitech.

Ongoing research programs and regulatory affairs would continue to be performed from Quebec as scheduled.

Stock option grant ---

Advitech announces that pursuant to the Corporation's stock option plan, it has granted a total of 1,250,000 stock options to employees and a consultant. These options have an exercise price between $0.10 and $0.16 per share and may be exercised during a period of five (5) years. This grant of options is subject to appropriate regulatory approvals.

Source: ADVITECH INC.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.